Insmed Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Insmed Inc's ROA in the second quarter of 2026?
Insmed Inc recorded a cumulative net loss of $-875 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -39.81%.

However, within the Healthcare sector 480 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3949, from total ROA ranking in the first quarter of 2026 at 4669.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-14.9 %	15.74 %	12.69 %	15.41 %	37.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-875	-1,184	-1,277	-1,184	-1,034
Return On Assets (TTM)	-39.81 %	-51.67 %	-57.51 %	-54.9 %	-49.78 %
INSM's Total Ranking	# 3949	# 4669	# 4068	# 4072	# 4190
Total Assets (TTM) in million	2,103	2,076	2,265	2,352	2,471
Seq. Total Assets Change	1.29 %	-8.33 %	-3.72 %	-4.8 %	37.76 %
Seq. Net Income Change	-	-	-	-	-

INSM's 5 Years Annual ROA >> Back to INSM Management Effectiveness >> Compare INSM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 191
Sector	# 481
Overall	# 3748

Return On Assets Statistics
High	Average	Low
-24.28 %	-44.78 %	-85.48 %
(Sep 30 2012)		(Jun 30 2017)

Financial Statements
Insmed Inc's Assets	$ 2,103 million	INSM's Balance sheet
Insmed Inc's Income	$ -13 million	Quarterly INSM's Income Statement
INSM's Income by Division		See INSM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	12.69 %	53.13 %	-19.82 %	35.05 %	58.2 %
Total Assets in million	2,265	2,009	1,312	1,637	1,212
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1,277	-914	-750	-482	-435
Annual Return On Assets	-56.38 %	-45.47 %	-57.12 %	-29.42 %	-35.86 %

INSM's 5 Years Annual ROA >> Back to INSM Management Effectiveness >> Compare INSM ROA to its Competitors

More Return On Assets Ratios
INSM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INSM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INSM's Competitors
Subscribers only: Roa for Insmed Inc's Suppliers
Subscribers only: Return On Assets for INSM's Customers

You may also want to know
INSM's Roi	INSM's Inventory Turnover Ratio	INSM's Growth Rates	INSM's Dividend Comparisons
	INSM's Profitability Ratios	INSM's Asset Turnover Ratio	INSM's Dividend Growth
INSM's Roe	INSM's Valuation Ratios	INSM's Financial Strength Ratios	INSM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:14:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.